Výsledky vyhledávání - "Arnd Mueller"

Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency

Autor: Juergen Wieland, Arnd Mueller, Hermann Allgaier, Beate Gertz, Rainer Winstel

Publikováno v: Drugs in R&D. 17:305-312

Ovaleap® (XM17) is a recombinant human follicle-stimulating hormone to treat infertility by inducing ovulation or controlled ovarian stimulation for assisted reproductive technology (ART) procedures. Ovaleap® (follitropin-α) was approved by the Eu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::384025a56de349ad8816de812a7d9b5c
https://doi.org/10.1007/s40268-017-0182-z

Zobrazit plný text záznamu

Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap

Autor: Rainer, Winstel, Juergen, Wieland, Beate, Gertz, Arnd, Mueller, Hermann, Allgaier

Publikováno v: Drugs in R&D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cfe8e049cec5681c6f8815173045d868
https://pubmed.ncbi.nlm.nih.gov/28386738

Zobrazit plný text záznamu

Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study

Autor: Peter Bias, Waldemar Kuczyński, Arnd Mueller, Thomas Strowitzki

Publikováno v: Reproductive Biology and Endocrinology : RB&E

Background: Ovaleap® (follitropin alfa), a recombinant human follicle-stimulating hormone intended for use in controlled ovarian stimulation in women undergoing assisted reproductive technologies (ART), showed therapeutic equivalence to Gonal-f® in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9edca8b28b355ddd9b22ad3e88fdf7d7
https://doi.org/10.1186/s12958-016-0164-y

Zobrazit plný text záznamu

Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation

Autor: Andreas Lammerich, Peter Bias, Arnd Mueller

Publikováno v: Reproductive Biology and Endocrinology : RB&E

Background XM17 is a recombinant human follicle-stimulating hormone (rhFSH) intended mainly for use in controlled ovarian hyperstimulation and the treatment of anovulation. The purpose of the current study was to establish bioequivalence, safety and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933b8ec3b6a5d96b9c527f5a329c5808
http://europepmc.org/articles/PMC4665917

Zobrazit plný text záznamu

Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)

Autor: Arnd Mueller, Peter Bias, Thomas Strowitzki, Waldemar Kuczyński

Publikováno v: Reproductive Biology and Endocrinology : RB&E

Background: Pharmacokinetic studies with XM17 (Ovaleap®), a recombinant human follicle-stimulating hormone (r-hFSH, follitropin alfa), have demonstrated good safety and tolerability in healthy women whose endogenous FSH levels were down-regulated wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebbfb6c584057a34f991e2447ffe0c98

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání